Pharmacokinetics of chlormethiazole in healthy volunteers and patients with cirrhosis of the liver - PubMed (original) (raw)

Clinical Trial

Pharmacokinetics of chlormethiazole in healthy volunteers and patients with cirrhosis of the liver

P J Pentikäinen et al. Eur J Clin Pharmacol. 1980 Apr.

No abstract available

PubMed Disclaimer

Similar articles

• Effect of cirrhosis of the liver on the pharmacokinetics of chlormethiazole.
  Pentikainen PJ, Neuvonen PJ, Tarpila S, Syvälahti E. Pentikainen PJ, et al. Br Med J. 1978 Sep 23;2(6141):861-3. doi: 10.1136/bmj.2.6141.861. Br Med J. 1978. PMID: 709096 Free PMC article.
• Pharmacokinetics of chlormethiazole in humans.
  Moore RG, Triggs EJ, Shanks CA, Thomas J. Moore RG, et al. Eur J Clin Pharmacol. 1975 Jun 13;8(5):353-7. doi: 10.1007/BF00562662. Eur J Clin Pharmacol. 1975. PMID: 1233235
• Kinetics of chlormethiazole in patients with alcohol withdrawal manifestations.
  Jostell KG, Agurell S, Hollister LE, Wermuth B. Jostell KG, et al. Clin Pharmacol Ther. 1978 Feb;23(2):181-7. doi: 10.1002/cpt1978232181. Clin Pharmacol Ther. 1978. PMID: 620478
• Pharmacokinetics of fluoroquinolones in hepatic failure.
  Montay G, Gaillot J. Montay G, et al. J Antimicrob Chemother. 1990 Oct;26 Suppl B:61-7. doi: 10.1093/jac/26.suppl_b.61. J Antimicrob Chemother. 1990. PMID: 2258353 Review.
• Drug disposition and liver disease.
  Wilkinson GR, Schenker S. Wilkinson GR, et al. Drug Metab Rev. 1975;4(2):139-75. doi: 10.3109/03602537508993754. Drug Metab Rev. 1975. PMID: 770104 Review. No abstract available.

Cited by

• A study of the relationship between serum bile acids and propranolol pharmacokinetics and pharmacodynamics in patients with liver cirrhosis and in healthy controls.
  Taegtmeyer AB, Haschke M, Tchambaz L, Buylaert M, Tschöpl M, Beuers U, Drewe J, Krähenbühl S. Taegtmeyer AB, et al. PLoS One. 2014 Jun 6;9(6):e97885. doi: 10.1371/journal.pone.0097885. eCollection 2014. PLoS One. 2014. PMID: 24906133 Free PMC article. Clinical Trial.
• Comparative pharmacokinetics and cardiovascular effects of tiapamil in healthy volunteers and patients with hepatic cirrhosis.
  Hinderling PH, Eckert M, Gasic S, Eichler HG, Pötzi R, Heizmann P. Hinderling PH, et al. Eur J Clin Pharmacol. 1986;31(4):397-404. doi: 10.1007/BF00613513. Eur J Clin Pharmacol. 1986. PMID: 3816918
• Effect of hepatic insufficiency on pharmacokinetics and drug dosing.
  Verbeeck RK, Horsmans Y. Verbeeck RK, et al. Pharm World Sci. 1998 Oct;20(5):183-92. doi: 10.1023/a:1008656930082. Pharm World Sci. 1998. PMID: 9820880 Review.
• Pharmacokinetics and dosage adjustment in patients with hepatic dysfunction.
  Verbeeck RK. Verbeeck RK. Eur J Clin Pharmacol. 2008 Dec;64(12):1147-61. doi: 10.1007/s00228-008-0553-z. Epub 2008 Sep 2. Eur J Clin Pharmacol. 2008. PMID: 18762933 Review.
• Distribution Clearance: Significance and Underlying Mechanisms.
  Weiss M. Weiss M. Pharm Res. 2024 Jul;41(7):1391-1400. doi: 10.1007/s11095-024-03738-7. Epub 2024 Jul 9. Pharm Res. 2024. PMID: 38981900 Free PMC article.

References

1. 1. J Pharmacol Exp Ther. 1974 Oct;191(1):17-24 - PubMed
2. 1. Drug Metab Rev. 1975;4(2):139-75 - PubMed
3. 1. Clin Pharmacol Ther. 1974 Sep;16(3):424-9 - PubMed
4. 1. N Engl J Med. 1975 Nov 13;293(20):1046-7 - PubMed
5. 1. Int J Clin Pharmacol Biopharm. 1976 Oct;14(3):225-30 - PubMed

Publication types

MeSH terms

Substances

LinkOut - more resources

• Full Text Sources

  • Springer